Retinoic Acid and Its Derivatives in Skin by Łukasz Szymański, Rafał Skopek, Małgorzata Palusińska, Tino Schenk, Sven Stengel, Sławomir Lewicki, Leszek Kraj, Paweł Kamiński, Arthur Zelent

“…Vitamin A derivatives have held promise in cancer treatment and ATRA is used in differentiation therapy of acute promyelocytic leukemia (APL). …”
Get full text

Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma by Jiajun Xie, Zifeng Wang, Wenjun Fan, Youping Liu, Fang Liu, Xiangbo Wan, Meiling Liu, Xuan Wang, Deshun Zeng, Yan Wang, Bin He, Min Yan, Zijian Zhang, Mengjuan Zhang, Zhijie Hou, Chunli Wang, Zhijie Kang, Wenfeng Fang, Li Zhang, Eric W-F Lam, Xiang Guo, Jinsong Yan, Yixin Zeng, Mingyuan Chen, Quentin Liu

“…Abstract Application of differentiation therapy targeting cellular plasticity for the treatment of solid malignancies has been lagging. …”
Get full text

Retinoic acid therapy resistance progresses from unilineage to bilineage in HL-60 leukemic blasts. by Holly A Jensen, Rodica P Bunaciu, Christopher N Ibabao, Rebecca Myers, Jeffrey D Varner, Andrew Yen

“…Here, we show that the R38+ and R38- HL-60 cell lines display a progressive reduced response to D3-induced differentiation therapy. Exploiting the biphasic dynamic of induced HL-60 differentiation, we examined if resistance-related defects occurred during the first 24 h (the early or "precommitment" phase) or subsequently (the late or "lineage-commitment" phase). …”
Get full text

4-Amino-2-trifluoromethyl-phenyl retinate inhibits proliferation, invasion, and migration of breast cancer cells by independently regulating CRABP2 and FABP5 by Ju J, Wang N, Wang J, Wu F, Ge J, Chen F

“…These findings may facilitate the use of differentiation therapy in BC. Keywords: ATPR, CRABP2, FABP5, breast cancer, proliferation, invasion, migration…”
Get full text

Immuno-Stimulating Activity of 1,25-Dihydroxyvitamin D in Blood Cells from Five Healthy People and in Blasts from Five Patients with Leukemias and Pre-Leukemic States by Aleksandra Marchwicka, Kuba Nowak, Anastasiia Satyr, Dariusz Wołowiec, Ewa Marcinkowska

“…Therefore, there is a need of milder treatment, named differentiation therapy, which might simulate the immune system of the patient. 1,25-Dihydroxyvitamin D, or low-calcemic analogs of this compound, were proposed as supporting therapy in acute leukemias. (2) Bone marrow blasts from patients with hematological malignancies, and leukocytes from healthy volunteers were ex vivo exposed to 1,25-dihydroxyvitamin D, and then their genomes and transcriptomes were investigated. (3) Our analysis indicates that 1,25-dihydroxyvitamin D regulates in blood cells predominantly genes involved in immune response, such as <i>CAMP</i> (cathelicidin antimicrobial peptide), <i>CP</i> (ceruloplasmin), <i>CXCL9</i> (C-X-C motif chemokine ligand 9), <i>CD14</i> (CD14 molecule) or <i>VMO1</i> (vitelline membrane outer layer 1 homolog). …”
Get full text

5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts by Vilma Dembitz, Hrvoje Lalic, Ivan Kodvanj, Barbara Tomic, Josip Batinic, Klara Dubravcic, Drago Batinic, Antonio Bedalov, Dora Visnjic

“…Recent development of inhibitors of mutated isocitrate dehydrogenase and dihydroorotate dehydrogenase (DHODH) has revived interest in differentiation therapy of non-APL AML. Our previous studies demonstrated that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAr) induced differentiation of monocytic cell lines by activating the ATR/Chk1 via pyrimidine depletion. …”
Get full text

A promising antitumor method: Targeting CSC with immune cells modified with CAR by Binjie Huang, Binjie Huang, Lele Miao, Lele Miao, Jie Liu, Jie Liu, Jiaxing Zhang, Jiaxing Zhang, Yumin Li, Yumin Li

“…Researchers have proposed many methods to inhibit or reduce CSCs, including monoclonal antibodies targeting specific surface molecules of CSCs, signal pathway inhibitors, and energy metabolic enzyme inhibitors and inducing differentiation therapy. Additionally, immunotherapy with immune cells engineered with a chimeric antigen receptor (CAR) showed favorable results. …”
Get full text

The generation of Paneth-like cells in colorectal cancer to alter T-cell responses by Ng, ME

“…Therefore, I propose that differentiation therapy could potentially augment current immuno-oncology approaches by enhancing the host immune response against CRC.…”

Ascl1 phospho-status regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma by Luke A. Wylie, Laura J. A. Hardwick, Tatiana D. Papkovskaia, Carol J. Thiele, Anna Philpott

“…This suggests that the maintenance of ASCL1 in its multiply phosphorylated state might prevent terminal differentiation in NB, which could offer new approaches for differentiation therapy in NB.…”
Get full text

miR-203 drives breast cancer cell differentiation by Nuria G. Martínez-Illescas, Silvia Leal, Patricia González, Osvaldo Graña-Castro, Juan José Muñoz-Oliveira, Alfonso Cortés-Peña, María Gómez-Gil, Zaira Vega, Verónica Neva, Andrea Romero, Miguel Quintela-Fandino, Eva Ciruelos, Consuelo Sanz, Sofía Aragón, Leisy Sotolongo, Sara Jiménez, Eduardo Caleiras, Francisca Mulero, Cristina Sánchez, Marcos Malumbres, María Salazar-Roa

“…Inducing cancer cell differentiation would abolish their self-renewal and invasive capacity and could be combined with the current standard of care, especially in poorly differentiated and aggressive tumors (with worst prognosis). However, differentiation therapy is still in its early stages and the intrinsic complexity of solid tumor heterogeneity demands innovative approaches in order to be efficiently translated into the clinic. …”
Get full text

Poorly differentiated thyroid carcinoma: a clinician’s perspective by Junyu Tong, Maomei Ruan, Yuchen Jin, Hao Fu, Lin Cheng, Qiong Luo, Zhiyan Liu, Zhongwei Lv, Libo Chen

“…Emerging therapeutics including molecular targeted therapy, differentiation therapy, and immunotherapy deserve further investigations to improve the prognosis of PDTC patients with advanced disease.…”
Get full text

SUMOylation disassembles the tetrameric pyruvate kinase M2 to block myeloid differentiation of leukemia cells by Li Xia, Yue Jiang, Xue-Hong Zhang, Xin-Ran Wang, Ran Wei, Kang Qin, Ying Lu

“…Our results establish PKM2 as an essential modulator of leukemia cell differentiation and a potential therapeutic target, which may offer synergistic effect with differentiation therapy in the treatment of leukemia.…”
Get full text

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma by Haitang Yang, Duo Xu, Zhang Yang, Feng Yao, Heng Zhao, Ralph A. Schmid, Ren-Wang Peng

“…Aberrant p53 attenuates differentiation and SETD2 loss acquires the dependency on EGFRs, highlighting the potential of differentiation therapy and pan-EGFR inhibitors for these subpopulations, respectively. …”
Get full text

Aberrant LETM1 elevation dysregulates mitochondrial functions and energy metabolism and promotes lung metastasis in osteosarcoma by Yulu Shi, Quan Kang, Hong Zhou, Xiaohan Yue, Yang Bi, Qing Luo

“…Osteosarcoma is a differentiation-deficient disease, and despite the unique advantages and great potential of differentiation therapy, there are only a few known differentiation inducers, and little research has been done on their targets. …”
Get full text

EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma by Ananya Pal, Jia Yu Leung, Gareth Chin Khye Ang, Vinay Kumar Rao, Luca Pignata, Huey Jin Lim, Maxime Hebrard, Kenneth TE Chang, Victor KM Lee, Ernesto Guccione, Reshma Taneja

“…Our study demonstrates that ERMS cells are vulnerable to EHMT2 inhibitors and suggest that targeting the EHMT2-DKK1-β-catenin node holds promise for differentiation therapy.…”
Get full text

Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells by Jacopo Albanesi, Nelida Ines Noguera, Cristina Banella, Tommaso Colangelo, Elisabetta De Marinis, Stefano Leone, Orazio Palumbo, Maria Teresa Voso, Paolo Ascenzi, Clara Nervi, Fabrizio Bianchi, Alessandra di Masi

“…APL is mainly managed by a differentiation therapy based on the administration of all-<i>trans</i> retinoic acid (ATRA) and arsenic trioxide (ATO). …”
Get full text

Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the Induction of Terminal Differentiation Markers and Apoptosis within Arsenite-Transformed Urothelial Ce... by Aaron A. Mehus, Madison Jones, Mason Trahan, Kaija Kinnunen, Kaitlyn Berwald, Becker Lindner, Sarmad Al-Marsoummi, Xu Dong Zhou, Scott H. Garrett, Donald A. Sens, Mary Ann Sens, Seema Somji

“…Further research is needed to explore the potential use of PVD with CIS as a differentiation therapy or alternative treatment for MIUC tumors that may have become resistant to CIS.…”
Get full text

Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation by Zhenzhen Guo, Luyao Sun, Haojie Xia, Shibin Tian, Mengyue Liu, Jiejie Hou, Jiahuan Li, Haihong Lin, Gangjun Du

“…Our results suggest that: 1. shikonin can down-regulate the WT1 protein level for leukemia differentiation therapy, and 2. the interaction between WT1 and CD34 proteins may be responsible for granulocyte/monocyte immaturity in HL-60 cells.…”
Get full text

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results o... by Ji Won Lee, Sanghoon Lee, Hee Won Cho, Youngeun Ma, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Eun Joo Cho, Suk-Koo Lee, Do Hoon Lim

“…Local radiotherapy, differentiation therapy with 13-cis-retinoic acid, and immunotherapy with interleukin-2 were administered after tandem HDCT/auto-SCT. …”
Get full text

PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma by Wenhu Li, Xianliao Zhang, Xinhua Xi, Yufa Li, Hong Quan, Shifeng Liu, Liqi Wu, Penghuan Wu, Wenxing Lan, Yongjun Shao, Haomiao Li, Kebing Chen, Zhengbo Hu

“…In conclusion, PLK2 is a potential target for differentiation therapy of OS with enriched TAp73.…”
Get full text